ClinicalTrials.gg
RecruitingNCT05547984CeMoD-primeUpdated Nov 12, 2026

Ceramic Modular Dual Mobility in Primary Total Hip Arthroplasty (THA)

An interventional study of Dual Mobility Cup and Standard Acetabular component in Coxarthrosis; Primary, sponsored by Aesculap AG. Recruiting at 1 site in Czechia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Aesculap AG (part of B. Braun) · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2022; still recruiting 4 years later.
Updated Nov 12, 2026Study contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

A randomized controlled trial comparing modular dual mobility inserts with ceramic multilayer coating versus standard polyethylene inserts for primary THA in a cementless acetabular cup

Read the detailed description

The aim of this study is to show in a randomized controlled trial that cobalt and chromium ion serum levels are comparable to the metal ion levels in patients with standard articulation with metal head. The metal on polyethylene articulation is accepted as standard articulation since many decades, and which is currently in the Czech Republic the most used combination. Most studies which focused on the topic of metal ion release from modular dual mobility systems do not present results of a control group with standard articulation hip implants.

02

Conditions studied

  • Coxarthrosis; Primary

Browse trials for

Keywords

  • Dual Mobility Cup
  • Total Hip Arthroplasty
03

In context

Osteoarthritis, Hip

642 studies on the registry are indexed under Osteoarthritis, Hip; 120 are open to participants now.

This study's planned enrollment of 100 is above the median of 90 across 458 interventional studies indexed under Osteoarthritis, Hip.

Browse Osteoarthritis, Hip studies →

Lead sponsor

Aesculap AG is the lead sponsor of 105 studies on the registry; 20 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primary coxarthrosis patients indicated for cementless total hip arthroplasty
  • Written informed patient consent

Exclusion criteria

Exclusion Criteria:

  • Hip trauma or revision surgery
  • Rheumatoid or neurologic disease
  • >35
  • Ongoing oncologic therapy
  • Preoperatively elevated Co or Cr serum levels >1.0 µg/L
  • Patients with other joint implants, or anticipated need for another joint replacement surgery within the study period
  • Acetabular cup size \<52 expected
  • Patients not able to mentally or physically comply with the study demands and follow-up visits
  • Patients \<18 years at surgery
  • Pregnancy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Dual Mobility Cup

    dual mobility articulation

    Device: Dual Mobility Cup

  • Active comparator
    Standard Acetabular component

    standard articulation with polyethylene + vitamin E inlay and metal head

    Device: Standard Acetabular component

Interventions

  • DeviceDual Mobility Cup

    Total hip arthroplasty (THA) is a successful and established therapy for coxarthrosis, rheumatic arthritis, hip fractures and femoral head necrosis. The acetabular implant for this arm is the Dual Mobility cup

    Also known as: Total Hip Arthroplasty

  • DeviceStandard Acetabular component

    Total hip arthroplasty (THA) is a successful and established therapy for coxarthrosis, rheumatic arthritis, hip fractures and femoral head necrosis. The acetabular implant for this arm is the standard device with polyethylene + vitamin E inlay and metal head

    Also known as: Total Hip Arthroplasty

06

What researchers measure

Primary outcomes

  1. Serum metal ion analysis (Cobalt)

    Cobalt ion levels in blood serum in measured in \[µg/L\], Comparison between the two groups

    Time frame: 12 months after surgery

  2. Serum metal ion analysis (Chromium)

    Chromium ion levels in blood serum in measured in \[µg/L\], Comparison between the two groups

    Time frame: 12 months after surgery

Secondary outcomes

  1. Change of functional outcome over three year follow-up period (Harris Hip Score)

    The Harris Hip Score (HHS) is one of the most used scores in total hip arthroplasty, mainly combining range of motion questions with questions regarding daily life activities. The HHS is a measure of dysfunction so the higher the score, the better the outcome for the individual. Results can be recorded and calculated online. The maximum score possible is 100, any result \<70 is considered a poor result; The HHS is an outcome measure administered by a qualified health care professional, such as a physician or a physical therapist.

    Time frame: 3 months, 12 months and 3 years postoperatively

  2. Gait analysis over time

    The gait lab analysis involves a high amount of recorded data and variables. Gait lab analyses are performed with the patients between the preoperative state, 3 months after surgery and 1 year postoperative. The Gait Profile Score (GPS) is used as a measure for the deviation in gait kinematics from a healthy patient population to compare the two treatment groups. Lower score values can be considered as a sign of better restoration of the physiological gait kinematics.

    Time frame: preoperative, 3 months and 12 months postoperatively

  3. Development of Patient satisfaction with surgery result over time

    Patient is asked for satisfaction with surgery result with a 4-point scale: very satisfied, satisfied, unsatisfied, very unsatisfied

    Time frame: at three examinations during Follow-Up (3 months postop, 1 year postop, 3 years postop)

  4. Radiologic Evaluation: Cup Inclination over time

    Inclination is the orientation of the cup in the coronal plane. The target acetabular cup inclination is a "safe zone" between 30-50° abduction (assessed on antero-posterior (ap) x-rays of the hip). The comparison of the intraoperatively achieved inclination and the inclination at different follow-up examinations allows prediction on longterm success.

    Time frame: immediately postoperative, 3 months, 12 months and 3 years postoperative

  5. Radiologic Evaluation: center of rotation

    Centre of Rotation (CoR) is defined as the zero position for the measurement of potential cup migration. Horizontal: Distance of CoR to ipsilateral teardrop; Vertical: Distance CoR to Inter-teardrop line; The comparison of the intraoperatively center of rotation and the center of rotation at different follow-up examinations allows prediction on longterm success.

    Time frame: immediately postoperative, 3 months, 12 months and 3 years postoperative

  6. Radiologic Evaluation: Radiolucencies around the cup

    Bony Osseointegration or conspicuous features of the cup are assessed on anterior-posterior and lateral x-rays of the cup and will be analysed according to the zones defined by Charnley. "Charnley" zones of the acetabular component are distinct zones used in assessment of aseptic loosening in total hip joint replacements. The radiolucencies are categorized to "none", "less than or equal to 2mm" and "more than 2 mm"

    Time frame: over follow-up period 3 months, 12 months and 3 years postoperative

  7. Radiological Outcome: Heterotopic Ossification

    Brooker classification divides heterotopic ossifications that form following total hip replacement to four classes. Class I: islands of bone within soft tissues around hip; Class II: bone spurs in pelvis or proximal end of femur leaving ≥1 cm between the opposing bone surfaces; Class III: bone spurs that extend from pelvis or the proximal end of femur, which reduce the space between the opposing bone surfaces to \<1cm; Class IV: ankylosis of the hip on x-ray

    Time frame: over follow-up period 3 months, 12 months and 3 years postoperative

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Sep 2027, 58 months after the start.

Of 227 interventional studies with no phase under Osteoarthritis, Hip, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 52. This study's planned 58 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2022
First posted
Sep 21, 2022
StartActual
Nov 21, 2022
Primary completionEst.
Sep 2027
CompletionEst.
Aug 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Contact
Study contact's phone or email changed: •••6195→•••1950; •••6195→•••1950. See the current contact
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Contact Study contact's phone or email changed: •••6195→•••1950; •••6195→•••1950. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05547984
Lead sponsor
Aesculap AG
Responsible party
Sponsor
First posted
Sep 21, 2022
Start date
Nov 21, 2022
Primary completion
Sep 2027 (estimated)
Completion
Aug 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

Lutz Dreyer, Dr.
Contact
info@aesculap.de
+497461950
Stefan Maenz, Dr.
Contact
info@aesculap.de
+497461950

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion